The second decade of prostate brachytherapy: Evidence and cost based outcomes

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 1, 2010, Pages 86-90

  Vigneri, Philip ^a   Herati, Amin S ^b   Potters, Louis ^a  

^a North Shore Long Island Jewish Health System ^*  (United States)

^b The Arthur Smith Institute for Urology   (United States)

Author keywords

Age; Brachytherapy; Multivariate analysis; Outcome; Prostate neoplasm; Risk factors

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

BRACHYTHERAPY; COSTS AND COST ANALYSIS; HUMANS; MALE; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 72549108815     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.02.003     Document Type: Review

References (31)

1. What Are the Key Statistics About Prostate Cancer?. American Cancer Society. http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_prostate_cancer_36.asp?sitearea= Accessed 2/13/2009
2. Scher H., Leibel S., and Fuks Z. Cancer of the prostate (2005), Williams and Wilkins, Philadelphia, Lippincott
3. Bill-Axelson A., Holmberg L., Filén F., et al. Radical prostatectomy vs. watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100 (2008) 1144-1154
4. Potters L., Morgenstern C., Calugaru E., et al. Twelve-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
5. Zelefsky M., Yamada Y., Fuks Z., et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 1028-1033
6. Jones J., Rewcastle J., Donnelly B., et al. Whole gland primary prostate cryoablation: Initial results from the cryo on-line data registry. J Urol 180 (2008) 554-558
7. Crawford E.D., and Barqawi A. Targeted focal therapy: A minimally invasive ablation technique for early prostate cancer. Oncology (Williston Park) 21 (2007) 27-32 Discussion 33-4, 39
8. Aronowitz J. Dawn of prostate brachytherapy: 1915-1930. Int J Radiat Oncol Biol Phys 54 (2002) 712-718
9. Zelefsky M., and Whitmore W.J. Long-term results of retropubic permanent 125 iodine implantation of the prostate for clinically localized prostatic cancer. J Urol 158 (1997) 23-29
10. Holm H., Torp-Pedersen S., and Myschetzky P. Transperineal seed implantation guided by biplanar transrectal ultrasound. Urology 36 (1990) 24-52
11. Stock R., Stone N., Wesson M., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32 (1995) 219-225
12. Zelefsky M., Yamada Y., Cohen G., et al. Postimplantation dosimetric analysis of permanent transperineal prostate implantation: Improved dose distributions with an intraoperative computer-optimized conformal planning technique. Int J Radiat Oncol Biol Phys 48 (2000) 601-608
13. Gelblum D.Y., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45 (1999) 59-67
14. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 453-460
15. Shapiro E., Rais-Bahrami S., Morgenstern C., et al. Long-term outcomes in younger men following permanent prostate brachytherapy. J Urol 181 (2009) 1665-1671
16. Baxter N., Tepper J., Durham S., et al. Increased risk of rectal cancer after prostate radiation: A population-based study. Gastroenterology 128 (2005) 819-824
17. Rapiti E., Fioretta G., Verkooijen H., et al. Increased risk of colon cancer after external radiation therapy for prostate cancer. Int J Cancer 123 (2008) 1141-1145
18. Moon K., Stukenborg G., Keim J., et al. Cancer incidence after localized therapy for prostate cancer. Cancer 107 (2006) 991-998
19. Abdel-Wahab M., Reis I., and Hamilton K. Second primary cancer after radiotherapy for prostate cancer-a SEER analysis of brachytherapy vs. external beam radiotherapy. Int J Radiat Oncol Biol Phys 72 (2008) 58-68
20. Acher P., Popert R., Nichol J., et al. Permanent prostate brachytherapy: Dosimetric results and analysis of a learning curve with a dynamic dose-feedback technique. Int J Radiat Oncol Biol Phys 65 (2006) 694-698
21. Ling C. Permanent implants using Au-198, Pd-103, and I-125: Radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 23 (1992) 81-87
22. Cho JS, Morgenstern C, Napolitano B, et al. Freedom from progression for patients receiving 125I vs. 103Pd for prostate brachytherapy. Int J Radiat Oncol Biol Phys (in press).
23. Pickett B., Kurhanewicz J., and Pouliot J. Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys 65 (2006) 65-72
24. Grimm P., Blasko J.C., Sylsvester J.E., et al. Ten-year biochemical (prostate-specific antigen) control of prostate cancer with I-125 brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
25. Blasko J., Grimm P., Sylsvester J., et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 573 (2000) 273-278
26. Stone N., Potters L., Davis B., et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73 (2009) 341-346
27. Stone N., Potters L., Davis B., et al. Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 69 (2007) 1472-1477
28. Lawton C., DeSilvio M., Roach M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69 (2007) 646-655
29. Sanda M., Dunn R., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
30. Seideman C., Morgenstern C., Napolitano B., et al. Erectile function in patients under 60, after prostate brachytherapy. Int J Radiat Oncol Biol Phys 72 (2008) S95
31. Hayes J., McMahon P., and Pearson S.D. Institute For Clinical And Economic Review; Final Appraisal Document. Brachytherapy and Proton Beam Therapy for Treatment of Clinically-Localized, Low Risk Prostate Cancer: Institute for Clinical and Economic Review. http://www.icer-review.org/index.php?option=com_content&task=view&id=18&Itemid=39 Accessed 1/21/09